相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Characterization of a novel human BFL-1-specific monoclonal antibody
Lahiru Gangoda et al.
CELL DEATH AND DIFFERENTIATION (2020)
Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL Inhibitor
Le Wang et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Metastatic Melanoma: Treatment and Survival in the US after the Introduction of Ipilimumab and Vemurafenib
Lindsey Enewold et al.
ONCOLOGY RESEARCH AND TREATMENT (2017)
Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy
Zeynep Eroglu et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2016)
Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM
Leona Rohrbeck et al.
CELL DEATH AND DIFFERENTIATION (2016)
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Andras Kotschy et al.
NATURE (2016)
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Treatment of NRAS-Mutant Melanoma
Douglas B. Johnson et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2015)
Role of the pro-survival molecule Bfl-1 in melanoma
C. K. Hind et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2015)
An Inducible Lentiviral Guide RNA Platform Enables the Identification of Tumor-Essential Genes and Tumor-Promoting Mutations In Vivo
Brandon J. Aubrey et al.
CELL REPORTS (2015)
BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition
Rizwan Haq et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Selective Induction of Cell Death in Melanoma Cell Lines through Targeting of Mcl-1 and A1
Daniela Senft et al.
PLOS ONE (2012)
PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas
John T. Lee et al.
PIGMENT CELL & MELANOMA RESEARCH (2010)
Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics
Mark S. Cragg et al.
NATURE REVIEWS CANCER (2009)
分享论文
